Inflammatory Bowel Disease
Mount Sinai and inflammatory bowel disease (IBD) have been synonymous since 1932 when the initial description of Crohn’s disease was made at The Mount Sinai Hospital. There is a strong base of clinical research, basic research, and probably one of the largest patient populations in the world. This access to patients allows us to perform unique studies looking at the control of mucosal inflammation (Colombel, Lira, Merad, Mehandru, and Cerutti), lymphocyte/ epithelial cell interactions (Berin and Lira), and the microbiome (Lira, Colombel, Faith, Clemente, Furtado, Merad, Alexandropoulos, and Cerutti).
Our investigators study the ontogeny and composition of mucosal immune cell populations (Merad, Alexandropoulos, and Mehandru), cellular migration (Lira, Furtado, and Mehandru), signaling (Ting, Chen and Xiong), apoptosis, and necrosis (Ting). In the area of immunoregulation, we study the function of specific activating or regulatory pathways (Lira and Xiong), role of complement in T cell function (Heeger) and the role of microRNAs in immune cell function (Brown).
Investigators with a major focus in IBD include: Konstantina Alexandropoulos, Judy H. Cho, Jose C. Clemente, Jean-Frédéric Colombel, Jeremiah Faith, Emilie K. Grasset, Peter Heeger, Sergio Lira, Miriam Merad, Guo-Cheng Yuan